{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T20:03:42Z","timestamp":1779134622367,"version":"3.51.4"},"reference-count":33,"publisher":"Zhejiang University Press","issue":"5","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Zhejiang Univ. Sci. B"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1631\/jzus.b1100366","type":"journal-article","created":{"date-parts":[[2012,5,2]],"date-time":"2012-05-02T02:34:41Z","timestamp":1335926081000},"page":"335-341","source":"Crossref","is-referenced-by-count":14,"title":["Antitumor effects of human interferon-alpha 2b secreted by recombinant bacillus Calmette-Gu\u00e9rin vaccine on bladder cancer cells"],"prefix":"10.1631","volume":"13","author":[{"given":"Guo-qing","family":"Ding","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-lan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhou-jun","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xie-lai","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan-wen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo-dong","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"635","published-online":{"date-parts":[[2012,5,3]]},"reference":[{"issue":"2","key":"3206_CR1","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3109\/08923970903300151","volume":"32","author":"A. Agarwal","year":"2010","unstructured":"Agarwal, A., Agrawal, U., Verma, S., Mohanty, N.K., Saxena, S., 2010. Serum Th1 and Th2 cytokine balance in patients of superficial transitional cell carcinoma of bladder pre- and post-intravesical combination immunotherapy. Immunopharmacol. Immunotoxicol., 32(2):348\u2013356. [doi:10.3109\/08923970903300151]","journal-title":"Immunopharmacol. Immunotoxicol."},{"issue":"4","key":"3206_CR2","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2217\/imt.10.32","volume":"2","author":"A.B. Alexandroff","year":"2010","unstructured":"Alexandroff, A.B., Nicholson, S., Patel, P.M., Jackson, A.M., 2010. Recent advances in bacillus Calmette-Guerin immunotherapy in bladder cancer. Immunotherapy, 2(4): 551\u2013560. [doi:10.2217\/imt.10.32]","journal-title":"Immunotherapy"},{"issue":"2","key":"3206_CR3","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/00002371-200403000-00005","volume":"27","author":"J. Arnold","year":"2004","unstructured":"Arnold, J., de Boer, E.C., O\u2019Donnell, M.A., B\u00f6hle, A., Brandau, S., 2004. Immunotherapy of experimental bladder cancer with recombinant BCG expressing interferon-gamma. J. Immunother., 27(2):116\u2013123. [doi:10.1097\/00002371-200403000-00005]","journal-title":"J. Immunother."},{"issue":"6","key":"3206_CR4","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/S0022-5347(01)63160-4","volume":"159","author":"A.S. Belldegrun","year":"1998","unstructured":"Belldegrun, A.S., Franklin, J.R., O\u2019Donnell, M.A., Gomella, L.G., Klein, E., Neri, R., Nseyo, U.O., Ratliff, T.L., Williams, R.D., 1998. Superficial bladder cancer: the role of interferon-alpha. J. Urol., 159(6):1793\u20131801. [doi:10.1016\/S0022-5347(01)63160-4]","journal-title":"J. Urol."},{"issue":"2","key":"3206_CR5","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1464-410X.1995.tb07309.x","volume":"75","author":"L. Bowyer","year":"1995","unstructured":"Bowyer, L., Hall, R.R., Reading, J., Marsh, M.M., 1995. The persistence of bacille Calmette-Guerin in the bladder after intravesical treatment for bladder cancer. Br. J. Urol., 75(2):188\u2013192. [doi:10.1111\/j.1464-410X.1995.tb07309.x]","journal-title":"Br. J. Urol."},{"issue":"1","key":"3206_CR6","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/1756-9966-27-78","volume":"27","author":"D.C. Chade","year":"2008","unstructured":"Chade, D.C., Borra, R.C., Nascimento, I.P., Villanova, F.E., Leite, L.C., Andrade, E., Srougi, M., Ramos, K.L., Andrade, P.M., 2008. Immunomodulatory effects of recombinant BCG expressing pertussis toxin on TNF-alpha and IL-10 in a bladder cancer model. J. Exp. Clin. Cancer Res., 27(1):78. [doi:10.1186\/1756-9966-27-78]","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"5","key":"3206_CR7","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1097\/01.ju.0000091826.83705.79","volume":"170","author":"E.C. Boer de","year":"2003","unstructured":"de Boer, E.C., Rooijakkers, S.J., Schamhart, D.H., Kurth, K.H., 2003. Cytokine gene expression in a mouse model: the first instillations with viable bacillus Calmette-Guerin determine the succeeding Th1 response. J. Urol., 170(5): 2004\u20132008. [doi:10.1097\/01.ju.0000091826.83705.79]","journal-title":"J. Urol."},{"issue":"5","key":"3206_CR8","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S0022-5347(05)66410-5","volume":"165","author":"C. Durek","year":"2001","unstructured":"Durek, C., Richter, E., Basteck, A., R\u00fcsch-Gerdes, S., Gerdes, J., Jocham, D., B\u00f6hle, A., 2001. The fate of bacillus Calmette-Guerin after intravesical instillation. J. Urol., 165(5):1765\u20131768. [doi:10.1016\/S0022-5347(05)66410-5]","journal-title":"J. Urol."},{"issue":"11","key":"3206_CR9","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1111\/j.1464-410X.2011.10234.x","volume":"108","author":"G. Gakis","year":"2011","unstructured":"Gakis, G., Todenhofer, T., Renninger, M., Schilling, D., Sievert, K.D., Schwentner, C., Stenzl, A., 2011. Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score. BJU Int., 108(11):1800\u20131805. [doi:10.1111\/j.1464-410X.2011.10234.x]","journal-title":"BJU Int."},{"issue":"4","key":"3206_CR10","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/00042307-200007000-00002","volume":"10","author":"W. Hassen","year":"2000","unstructured":"Hassen, W., Droller, M.J., 2000. Current concepts in assessment and treatment of bladder cancer. Curr. Opin. Urol., 10(4):291\u2013299. [doi:10.1097\/00042307-200007000-00002]","journal-title":"Curr. Opin. Urol."},{"issue":"3","key":"3206_CR11","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1097\/01.ju.0000103924.93206.93","volume":"171","author":"C.F. Lee","year":"2004","unstructured":"Lee, C.F., Chang, S.Y., Hsieh, D.S., Yu, D.S., 2004. Immunotherapy for bladder cancer using recombinant bacillus Calmette-Guerin DNA vaccines and interleukin-12 DNA vaccine. J. Urol., 171(3):1343\u20131347. [doi:10.1097\/01.ju.0000103924.93206.93]","journal-title":"J. Urol."},{"issue":"10","key":"3206_CR12","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1007\/s00262-009-0673-z","volume":"58","author":"W. Liu","year":"2009","unstructured":"Liu, W., O\u2019Donnell, M.A., Chen, X., Han, R., Luo, Y., 2009. Recombinant bacillus Calmette-Gu\u00e9rin (BCG) expressing interferon-alpha 2b enhances human mononuclear cell cytotoxicity against bladder cancer cell lines in vitro. Cancer Immunol. Immunother., 58(10):1647\u20131655. [doi:10.1007\/s00262-009-0673-z]","journal-title":"Cancer Immunol. Immunother."},{"issue":"6","key":"3206_CR13","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1128\/CDLI.3.6.761-768.1996","volume":"3","author":"Y. Luo","year":"1996","unstructured":"Luo, Y., Szilvasi, A., Chen, X., deWolf, W.C., O\u2019Donnell, M.A., 1996. A novel method for monitoring Mycobacterium bovis BCG trafficking with recombinant BCG expressing green fluorescent protein. Clin. Diagn Lab. Immunol., 3(6):761\u2013768.","journal-title":"Clin. Diagn Lab. Immunol."},{"issue":"2","key":"3206_CR14","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1046\/j.1365-2249.2001.01428.x","volume":"123","author":"Y. Luo","year":"2001","unstructured":"Luo, Y., Chen, X., Han, R., O\u2019Donnell, M.A., 2001. Recombinant bacille Calmette-Gu\u00e9rin (BCG) expressing human interferon-alpha 2b demonstrates enhanced immunogenicity. Clin. Exp. Immunol., 123(2):264\u2013270. [doi:10.1046\/j.1365-2249.2001.01428.x]","journal-title":"Clin. Exp. Immunol."},{"issue":"1","key":"3206_CR15","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1365-2249.2004.02522.x","volume":"137","author":"Y. Luo","year":"2004","unstructured":"Luo, Y., Yamada, H., Chen, X., Ryan, A.A., Evanoff, D.P., Triccas, J.A., O\u2019Donnell, M.A., 2004. Recombinant Mycobacterium bovis bacillus Calmette-Gu\u00e9rin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity. Clin. Exp. Immunol., 137(1): 24\u201334. [doi:10.1111\/j.1365-2249.2004.02522.x]","journal-title":"Clin. Exp. Immunol."},{"issue":"2","key":"3206_CR16","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","volume":"56","author":"P.U. Malmstr\u00f6m","year":"2009","unstructured":"Malmstr\u00f6m, P.U., Sylvester, R.J., Crawford, D.E., Friedrich, M., Krege, S., Rintala, E., Solsona, E., di Stasi, S.M., Witjes, J.A., 2009. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur. Urol., 56(2):247\u2013256. [doi:10.1016\/j.eururo.2009.04.038]","journal-title":"Eur. Urol."},{"issue":"2","key":"3206_CR17","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1179\/joc.2002.14.2.194","volume":"14","author":"N.K. Mohanty","year":"2002","unstructured":"Mohanty, N.K., Malhotra, V., Nayak, R.L., Arora, R.P., 2002. Combined low-dose intravesical immunotherapy (BCG+ interferon alpha-2b) in the management of superficial transitional cell carcinoma of the urinary bladder: a five-year follow-up. J. Chemother., 14(2):194\u2013197.","journal-title":"J. Chemother."},{"issue":"2","key":"3206_CR18","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","volume":"116","author":"A. Morales","year":"1976","unstructured":"Morales, A., Eidinger, D., Bruce, A.W., 1976. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J. Urol., 116(2):180\u2013183.","journal-title":"J. Urol."},{"issue":"2","key":"3206_CR19","first-page":"425","volume":"8","author":"A. Moro","year":"2001","unstructured":"Moro, A., Perea, S.E., Pantoja, C., Santos, A., Ara\u00f1a, M.D., Serrano, M., 2001. IFNalpha 2b induces apoptosis and proteasome-mediated degradation of p27Kip1 in a human lung cancer cell line. Oncol. Rep., 8(2):425\u2013429.","journal-title":"Oncol. Rep."},{"issue":"3","key":"3206_CR20","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1097\/01.ju.0000136446.37840.0a","volume":"172","author":"M.A. O\u2019Donnell","year":"2004","unstructured":"O\u2019Donnell, M.A., Lilli, K., Leopold, C., 2004. Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer. J. Urol., 172(3):888\u2013893. [doi:10.1097\/01.ju.0000136446.37840.0a]","journal-title":"J. Urol."},{"issue":"12","key":"3206_CR21","first-page":"2489","volume":"58","author":"L.M. Pfeffer","year":"1998","unstructured":"Pfeffer, L.M., Dinarello, C.A., Herberman, R.B., Williams, B.R., Borden, E.C., Bordens, R., Walter, M.R., Nagabhushan, T.L., Trotta, P.P., Pestka, S., 1998. Biological properties of recombinant \u03b1-interferons: 40th anniversary of the discovery of interferons. Cancer Res., 58(12): 2489\u20132499.","journal-title":"Cancer Res."},{"issue":"S2","key":"3206_CR22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000474916","volume":"21","author":"T.L. Ratliff","year":"1992","unstructured":"Ratliff, T.L., 1992. Role of the immune response in BCG for bladder cancer. Eur. Urol., 21(S2):17\u201321.","journal-title":"Eur. Urol."},{"issue":"1","key":"3206_CR23","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0022-5347(05)64044-X","volume":"169","author":"O. Shahin","year":"2003","unstructured":"Shahin, O., Thalmann, G.N., Rentsch, C., Mazzucchelli, L., Studer, U.E., 2003. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J. Urol., 169(1):96\u2013100. [doi:10.1016\/S0022-5347(05)64044-X]","journal-title":"J. Urol."},{"issue":"3","key":"3206_CR24","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ctrv.2009.12.005","volume":"36","author":"M.D. Shelley","year":"2010","unstructured":"Shelley, M.D., Mason, M.D., Kynaston, H., 2010. Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses. Cancer Treat. Rev., 36(3):195\u2013205. [doi:10.1016\/j.ctrv.2009.12.005]","journal-title":"Cancer Treat. Rev."},{"issue":"2","key":"3206_CR25","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1442-2042.2007.01696.x","volume":"14","author":"Y. Shintani","year":"2007","unstructured":"Shintani, Y., Sawada, Y., Inagaki, T., Kohjimoto, Y., Uekado, Y., Shinka, T., 2007. Intravesical instillation therapy with bacillus Calmette-Gu\u00e9rin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Gu\u00e9rin immunotherapy. Int. J. Urol., 14(2):140\u2013146. [doi:10.1111\/j.1442-2042.2007.01696.x]","journal-title":"Int. J. Urol."},{"issue":"4","key":"3206_CR26","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1097\/01.ju.0000131944.52354.63","volume":"172","author":"H. Suttmann","year":"2004","unstructured":"Suttmann, H., Jacobsen, M., Reiss, K., Jocham, D., Bohle, A., Brandau, S., 2004. Mechanisms of bacillus Calmette-Guerin mediated natural killer cell activation. J. Urol., 172(4):1490\u20131495. [doi:10.1097\/01.ju.0000131944.52354.63]","journal-title":"J. Urol."},{"issue":"2","key":"3206_CR27","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0022-5347(05)65966-6","volume":"166","author":"A.P. Meijden van der","year":"2001","unstructured":"van der Meijden, A.P., Brausi, M., Zambon, V., Kirkels, W., de Balincourt, C., Sylvester, R., 2001. Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial. J. Urol., 166(2):476\u2013481. [doi:10.1016\/S0022-5347(05)65966-6]","journal-title":"J. Urol."},{"issue":"6","key":"3206_CR28","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1128\/IAI.72.6.3336-3343.2004","volume":"72","author":"P.B. Varaldo","year":"2004","unstructured":"Varaldo, P.B., Leite, L.C., Dias, W.O., Miyaji, E.N., Torres, F.I., Gebara, V.C., Arm\u00f4a, G.R., Campos, A.S., Matos, D.C., Winter, N., et al., 2004. Recombinant Mycobacterium bovis BCG expressing the Sm14 antigen of Schistosoma mansoni protects mice from cercarial challenge. Infect. Immun., 72(6):3336\u20133343. [doi:10.1128\/IAI.72.6.3336-3343.2004]","journal-title":"Infect. Immun."},{"issue":"8","key":"3206_CR29","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1128\/CVI.00112-09","volume":"16","author":"Y. Xu","year":"2009","unstructured":"Xu, Y., Liu, W., Shen, H., Yan, J., Qu, D., Wang, H., 2009. Recombinant Mycobacterium bovis BCG expressing the chimeric protein of antigen 85B and ESAT-6 enhances the Th1 cell-mediated response. Clin. Vaccine Immunol., 16(8):1121\u20131126. [doi:10.1128\/CVI.00112-09]","journal-title":"Clin. Vaccine Immunol."},{"issue":"1","key":"3206_CR30","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/BF02550276","volume":"30","author":"F. Yal\u00e7inkaya","year":"1998","unstructured":"Yal\u00e7inkaya, F., Kamis, L., Ozteke, O., Gunlusoy, B., Yigitbasi, O., Unal, S., 1998. Prospective randomized comparison of intravesical BCG therapy with standard dose versus low doses in superficial bladder cancer. Int. Urol. Nephrol., 30(1):41\u201344. [doi:10.1007\/BF02550276]","journal-title":"Int. Urol. Nephrol."},{"issue":"2","key":"3206_CR31","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S0022-5347(05)67417-4","volume":"164","author":"H. Yamada","year":"2000","unstructured":"Yamada, H., Matsumoto, S., Matsumoto, T., Yamada, T., Yamashita, U., 2000. Murine IL-2 secreting recombinant Bacillus Calmette-Guerin augments macrophage-mediated cytotoxicity against murine bladder cancer MBT-2. J. Urol., 164(2):526\u2013531. [doi:10.1016\/S0022-5347(05)67417-4]","journal-title":"J. Urol."},{"issue":"2","key":"3206_CR32","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.juro.2006.09.074","volume":"177","author":"D.S. Yu","year":"2007","unstructured":"Yu, D.S., Lee, C.F., Chang, S.Y., 2007. Immunotherapy for orthotopic murine bladder cancer using bacillus Calmette-Guerin recombinant protein Mpt-64. J. Urol., 177(2):738\u2013742. [doi:10.1016\/j.juro.2006.09.074]","journal-title":"J. Urol."},{"issue":"6","key":"3206_CR33","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.4049\/jimmunol.163.6.3169","volume":"163","author":"D. Zella","year":"1999","unstructured":"Zella, D., Barabitskaja, O., Casareto, L., Romerio, F., Secchiero, P., Reitz, M.S.Jr., Gallo, R.C., Weichold, F.F., 1999. Recombinant IFN-alpha (2b) increases the expression of apoptosis receptor CD95 and chemokine receptors CCR1 and CCR3 in monocytoid cells. J. Immunol., 163(6):3169\u20133175.","journal-title":"J. Immunol."}],"container-title":["Journal of Zhejiang University SCIENCE B"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1631\/jzus.B1100366.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1631\/jzus.B1100366\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1631\/jzus.B1100366","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T11:26:54Z","timestamp":1687433214000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1631\/jzus.B1100366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["3206"],"URL":"https:\/\/doi.org\/10.1631\/jzus.b1100366","relation":{},"ISSN":["1673-1581","1862-1783"],"issn-type":[{"value":"1673-1581","type":"print"},{"value":"1862-1783","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}